These findings are consistent with the SOLAR-135 and BYLieve36 clinical trials, which demonstrated the benefit of alpelisib in hormone receptor-positive, HER2-negative breast cancer harboring PIK3CA mutations. Here, NR4A1 is linked to breast carcinoma.